ArticleThe Journal of infectious diseases2018
A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Mapping FirstbioRxiv : the preprint server for biology · 2026Article
- Systemic and Mucosal Immune Responses From Serotype-Switched Viral-Vectored Ebola Vaccines.Journal of medical virology · 2026Article
- Comparison of Systemic and Mucosal Synchronous Immunization with Replicating Single-cycle Adenoviruses and SOSIP Protein HIV-1 Vaccines.Research square · 2026Article
- Establishment and characterization of a replication-restricted modified African swine fever virus.Microbiology spectrum · 2026Article
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Research advances in replication-deficient viral vector vaccines.Frontiers in veterinary science · 2025Review
- Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.Vaccines · 2024Article
- Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.Heliyon · 2024Review
- Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.Science advances · 2022Article
- Viral vector vaccines.Current opinion in immunology · 2022Review
- Review
- Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.Pharmaceutics · 2021Review
- Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.Vaccines · 2020Review
- Article
- Retargeting adenoviruses for therapeutic applications and vaccines.FEBS letters · 2020Review
- Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope.Vaccines · 2020Article
- Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.Journal of virology · 2019Article
- Article
- Will a Single-Cycle Adenovirus Vaccine Be Effective Against Ebola Virus?The Journal of infectious diseases · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. We recently described a "single-cycle" adenovirus (SC-Ad) vector that amplifies antigen genes like RC-Ad, but that avoids the risk of adenovirus infection. Here we have tested an SC-Ad6 vector expressing the glycoprotein (GP) from a 2014 EBOV strain in mice, hamsters, and rhesus macaques. We show that SC-Ad6-EBOV GP induces a high level of serum antibodies in all species and mediates significant protection against pseudo-challenge with rVSV-EBOV expressing luciferase in mice and hamsters. These data suggest that SC-Ad6-EBOV GP may be useful during future EBOV outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.